Prabhawathi et al., 2019 - Google Patents
Design of antimicrobial polycaprolactam nanocomposite by immobilizing subtilisin conjugated Au/Ag core-shell nanoparticles for biomedical applicationsPrabhawathi et al., 2019
- Document ID
- 17307160855543261729
- Author
- Prabhawathi V
- Sivakumar P
- Boobalan T
- Manohar C
- Doble M
- Publication year
- Publication venue
- Materials Science and Engineering: C
External Links
Snippet
Preparation of the gold core and silver shell NP (AuAgNP) is challenging because of the facile oxidation of silver. Here such a NP is carefully synthesized and conjugated with subtilisin to arrive at a stable spherical material of 120–130 nm in diameter (AuAgSNP). A …
- 229920002292 Nylon 6 0 title abstract description 55
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
- A61K47/48853—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/30—Macromolecular compounds
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin, zein
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Prabhawathi et al. | Design of antimicrobial polycaprolactam nanocomposite by immobilizing subtilisin conjugated Au/Ag core-shell nanoparticles for biomedical applications | |
| Makvandi et al. | Metal‐based nanomaterials in biomedical applications: antimicrobial activity and cytotoxicity aspects | |
| Choi et al. | Drug delivery strategies for antibiofilm therapy | |
| Gao et al. | Potentials of nanotechnology in treatment of methicillin-resistant Staphylococcus aureus | |
| Durán et al. | Silver nanoparticles: A new view on mechanistic aspects on antimicrobial activity | |
| JP6423833B2 (en) | Composition and method of antibacterial metal nanoparticles | |
| Qayyum et al. | Nanoparticles vs. biofilms: a battle against another paradigm of antibiotic resistance | |
| Weldrick et al. | Enhanced clearing of wound-related pathogenic bacterial biofilms using protease-functionalized antibiotic nanocarriers | |
| Raghupathi et al. | Size-dependent bacterial growth inhibition and mechanism of antibacterial activity of zinc oxide nanoparticles | |
| Goswami et al. | Role of biogenic silver nanoparticles in disruption of cell–cell adhesion in Staphylococcus aureus and Escherichia coli biofilm | |
| Chavan et al. | Ampicillin-mediated functionalized gold nanoparticles against ampicillin-resistant bacteria: strategy, preparation and interaction studies | |
| Busi et al. | Microbially synthesized nanoparticles as next generation antimicrobials: scope and applications | |
| Liu et al. | Antimicrobial nanomaterials against biofilms: an alternative strategy | |
| Armenia et al. | Magnetic nanoconjugated teicoplanin: a novel tool for bacterial infection site targeting | |
| Binupriya et al. | Myco-crystallization of silver ions to nanosized particles by live and dead cell filtrates of Aspergillus oryzae var. viridis and its bactericidal activity toward Staphylococcus aureus KCCM 12256 | |
| Bhargava et al. | Superior bactericidal efficacy of fucose-functionalized silver nanoparticles against Pseudomonas aeruginosa PAO1 and prevention of its colonization on urinary catheters | |
| Huang et al. | Enhanced antibacterial activity of se nanoparticles upon coating with recombinant spider silk protein eADF4 (κ16) | |
| Jampilek et al. | Advances in nanostructures for antimicrobial therapy | |
| Khorsandi et al. | A mechanistic perspective on targeting bacterial drug resistance with nanoparticles | |
| Weldrick et al. | Advanced Alcalase-Coated Clindamycin-Loaded Carbopol Nanogels for Removal of Persistent Bacterial Biofilms | |
| Borehalli Mayegowda et al. | Eco-friendly synthesized nanoparticles as antimicrobial agents: an updated review | |
| Alsaggaf et al. | Synergistic antimicrobial action of phyco-synthesized silver nanoparticles and nano-fungal chitosan composites against drug resistant bacterial pathogens | |
| Chakraborty et al. | 3, 6-Di (pyridin-2-yl)-1, 2, 4, 5-tetrazine (pytz)-capped silver nanoparticles (TzAgNPs) inhibit biofilm formation of Pseudomonas aeruginosa: a potential approach toward breaking the wall of biofilm through reactive oxygen species (ROS) generation | |
| Masadeh et al. | Synergistic Effect of Silver Nanoparticles with Antibiotics for Eradication of Pathogenic Biofilms | |
| Bacchu et al. | Ceftizoxime loaded ZnO/l-cysteine based an advanced nanocarrier drug for growth inhibition of Salmonella typhimurium |